Consequently, these observations have led to diabetes therapy development in the form of GLP-1 receptor (GLP-1R) agonists for the treatment of type 2 diabetes mellitus and, subsequently, for obesity [9]. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.